Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm?
{{output}}
Since the global withdrawal of rofecoxib (Vioxx) in 2004, concerns about public health effects of direct-to-consumer advertising (DTCA) have grown. A systematic review of the research evidence on behavioral, health, and cost effects, published in 2005, found f... ...
